Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study

ConclusionsThis real-world analysis suggests differences exist in persistence between patients treated with various GLP-1 RAs. Among the investigated treatments, patients prescribed exBID recorded the lowest and those prescribed DULA the highest persistence with therapy.FundingEli Lilly and Co., Indianapolis, IN, USA.

Source: Diabetes Therapy - March 10, 2018 Category: Endocrinology Source Type: research